Skip to main content
SpringerLink
Log in

Medical Management of Oral Submucous Fibrosis

  • Chapter
  • First Online:
Oral Submucous Fibrosis

Part of the book series: Textbooks in Contemporary Dentistry ((TECD))

Abstract

Oral submucous fibrosis (OSF) is an insidious, chronic, progressive, and debilitating disease characterized by fibrotic changes in the oral mucosa. The medical management of OSF include dietary supplements immunomodulatory/anti-inflammatory agents, proteolytic agents, vasodilators, immunomodulators, and anti-cytokines. Herbal preparations have also been used in the medical management of OSF [1–4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tilakaratne WM, Ekanayaka RP, Warnakulasuriya S. Oral submucous fibrosis: a historical perspective and a review on etiology and pathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(2):178–91.

    Article  PubMed  Google Scholar 

  2. Kerr AR, Warnakulasuriya S, Mighell AJ, Dietrich T, Nasser M, Rimal J, Jalil A, Bornstein MM, Nagao T, Fortune F, Hazarey VH, Reichart PA, Silverman S, Johnson NW. A systematic review of medical interventions for oral submucous fibrosis and future research opportunities. Oral Dis. 2011;17(Suppl. 1):42–57.

    Article  PubMed  Google Scholar 

  3. Warnakulasuriya S, Kerr AR. Oral submucous fibrosis: a review of the current management and possible directions for novel therapies. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(2):232–41.

    Article  PubMed  Google Scholar 

  4. More CB, Jatti Patil D, Rao NR. Medicinal management of oral submucous fibrosis in the past decade: a systematic review. J Oral Biol Craniofac Res. 2020;10(4):552–68.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Awan KH, Patil S, Habib SR, Pejcic A, Zain RB. Evaluation of medicinal interventions for the management of oral submucous fibrosis: a systematic review of the literature. J Contemp Dent Pract. 2014;15(6):812–7.

    Article  PubMed  Google Scholar 

  6. Aishwarya V, Amudhan A, Amudhan A. Management of oral submucous fibrosis – An update. Eur J Mol Clin Med. 2020;7(5):1380–92.

    Google Scholar 

  7. Tsai CC, Ma RH, Shieh TY. Deficiency in collagen and fibronectin phagocytosis by human buccal mucosa fibroblasts in vitro as a possible mechanism for oral submucous fibrosis. J Oral Pathol Med. 1999;28(2):59–63.

    Article  PubMed  Google Scholar 

  8. Alora Veedu R, Balan A, Sankar SP. A randomized double-blind, multiple-arm trial comparing the efficacy of submucosal injections of hyaluronidase, dexamethasone, and combination of dexamethasone and hyaluronidase in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol. Oral Radiol. 2015;120(5):588–593 e1.

    Article  Google Scholar 

  9. Panigrahi R, Maheshwari A. A prospective, randomized double-blind study comparing intralesional triamcinolone acetonide and hyaluronidase combination versus triamcinolone acetonide alone in the treatment of oral submucosal fibrosis. J Pharm Biomed Sci. 2014;4(4):365–70.

    Google Scholar 

  10. Goel S, Ahmed J. A comparative study on efficacy of different treatment modalities of oral submucous fibrosis evaluated by clinical staging in population of Southern Rajasthan. J Canc Res Therapeut. 2015;11(1):113–8.

    Article  Google Scholar 

  11. Jiang XW, Zhang Y, Yang SK, Zhang H, Lu K, Sun GL. Efficacy of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2013;115:339–44.

    Article  Google Scholar 

  12. Jirge V, Ali SM, Anshumalee N. Levamisole and antioxidants in management of oral submucous fibrosis: a comparative study. J Ind Acad Oral Med Radiol. 2009;20:135–9.

    Article  Google Scholar 

  13. Shinge AA, Talreja PK, Das D, Navalkar A, Talreja PS, Kakade A. Comparative evaluation of the efficacy of systemic levamisole and antioxidant in the management of oral submucous fibrosis – A randomized control trial. J Adv Clin Res Insights. 2019;6(2):33–8.

    Article  Google Scholar 

  14. Tai YS, Liu BY, Wang JT, Sun A, Kwan HW, Chiang CP. Oral administration of milk from cows immunized with human intestinal bacteria leads to significant improvements of symptoms and signs in patients with oral submucous fibrosis. J Oral Pathol Med. 2001;30:618–25.

    Article  PubMed  Google Scholar 

  15. Seema B. Etiopathogenesis and management of oral submucous fibrosis. Qual Primary Care. 2015;23(6):327–32.

    Google Scholar 

  16. Arakeri G, Rai KK, Boraks G, Patil SG, Aljabab AS, Merkx MAW, Carrozzo M, Brennan PA. Current protocols in the management of oral submucous fibrosis: an update. J Oral Pathol Med. 2017;46(6):418–23.

    Article  PubMed  Google Scholar 

  17. Chole RH, Gondivkar SM, Gadbail AR, et al. Review of drug treatment of oral submucous fibrosis. Oral Oncol. 2012;48:393–8.

    Article  PubMed  Google Scholar 

  18. Angadi PV, Rao S. Management of oral submucous fibrosis: an overview. Oral Maxillofac Surg. 2010;14:133–42.

    Article  PubMed  Google Scholar 

  19. Krishnamoorthy B, Khan M. Management of oral submucous fibrosis by two different drug regimens: a comparative study. Dent Res J. 2013;10:527–32.

    Google Scholar 

  20. Cox S, Zoellner H. Physiotherapeutic treatment improves oral opening in oral submucous fibrosis. J Oral Pathol Med. 2009;38:220–6.

    Article  PubMed  Google Scholar 

  21. James L, Shetty A, Rishi D, Abraham M. Management of oral submucous fibrosis with injection of hyaluronidase and dexamethasone in Grade III oral submucous fibrosis: a retrospective study. J Int Oral Health. 2015;7(8):82–5.

    PubMed  PubMed Central  Google Scholar 

  22. Gupta D, Sharma SC. Oral submucous fibrosis--a new treatment regimen. J Oral Maxillofac Surg 1988;46(10):830–833.

    Google Scholar 

  23. Ayub S, Siddiqui S, Abrar SK, Atif M, Raheel Allana R, Ahmad M. Effectiveness the combination therapy of chymotrypsin and dexamethasone vs dexamethasone alone in patients with oral sub mucous fibrosis. Rawal Med J. 2021;46(4):932–5.

    Google Scholar 

  24. Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009;361(10):968–77.

    Article  PubMed  Google Scholar 

  25. Lin HJ, Lin JC. Treatment of oral submucous fibrosis by collagenase: effects on oral opening and eating function. Oral Dis. 2007;13:407–13.

    Article  PubMed  Google Scholar 

  26. Saso L, Reza A, Ng E, Nguyen K, Lin S, Zhang P, Fantozzi PJ, Armagan G, Romeo U, Cirillo N. A comprehensive analysis of the role of oxidative stress in the pathogenesis and chemoprevention of oral submucous fibrosis. Antioxidants (Basel). 2022;11(5):868.

    Article  PubMed  Google Scholar 

  27. Heber D, Lu QY. Overview of mechanisms of action of lycopene. Exp Biol Med (Maywood). 2002;227(10):920–3.

    Article  PubMed  Google Scholar 

  28. Singh M, Krishanappa R, Bagewadi A, Keluskar V. Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncol. 2004;40:591–6.

    Article  PubMed  Google Scholar 

  29. Saawarn N, Shashikanth MC, Saawarn S, Jirge V, Chaitanya NC, Pinakapani R. Lycopene in the management of oral lichen planus: a placebo-controlled study. Indian J Dent Res. 2011;22:639–43.

    Article  PubMed  Google Scholar 

  30. Kumar A, Bagewadi A, Keluskar V, Singh M. Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:207–13.

    Article  PubMed  Google Scholar 

  31. Karemore TV, Motwani M. Evaluation of the effect of newer antioxidant lycopene in the treatment of oral submucous fibrosis. Indian J Dent Res. 2012;23:524–8.

    Article  PubMed  Google Scholar 

  32. Beenakumary TP, AG T, Varghese M, Raghavan R, Vm MN, Pius A. Evaluation of therapeutic efficacy of different treatment modalities in oral submucous fibrosis: a comparative study. J Contemp Dent Pract. 2019;20(3):390–4.

    Article  Google Scholar 

  33. Johny J, Bhagvandas SC, Mohan SP, Punathil S, Moyin S, Bhaskaran MK. Comparison of efficacy of lycopene and lycopene-hyaluronidase combination in the treatment of oral submucous fibrosis. J Pharm Bioallied Sci. 2019;11(2):S260–4.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Saran G, Umapathy D, Misra N, et al. A comparative study to evaluate the efficacy of lycopene and curcumin in oral submucous fibrosis patients: a randomized clinical trial. Indian J Dent Res. 2018;29(3):303–12.

    Article  PubMed  Google Scholar 

  35. Selvam NP, Dyanand AA. Lycopene in the management of oral submucous fibrosis. Asian J Pharmaceut Clin Res. 2013;6(3):58–61.

    Google Scholar 

  36. Elizabeth N, Gurumani S, Bala AG, Tukalan G. A comparative study between management of oral submucous fibrosis. J Evol Med Dent Sci. 2014;3(47):11344–8.

    Article  Google Scholar 

  37. Subramaniam AV, Subramaniam T, Agrawal N. Assessment of the effectiveness of antioxidant therapy(lycopene) and therapeutic ultrasound in the treatment of oral submucous fibrosis. Int J Pharm Therapeut. 2014;5(5):344–50.

    Google Scholar 

  38. Singh D, Shashikanth MC, Misra N, Agrawal S. Lycopene and intralesional betamethasone injections in the management of oral submucous fibrosis. J Indian Acad Oral Med Radiol. 2014;26:264–8.

    Article  Google Scholar 

  39. Arshad O, Siddiqi KM, Rana ZA. Oral submucous fibrosis: comparison of different treatment modalities. Pak Oral Dental J. 2015;35:3.

    Google Scholar 

  40. Bhowmick D, Kumar S, Nasreen S, Saba R, Iqbal H, Bhatia LK. Comparative evaluation of Lycopene-Hyaluronidase combination and Lycopene alone in the treatment of OSMF. Int J Health Clin Res. 2021;4(5):102–5.

    Google Scholar 

  41. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of turmeric (Curcuma longa). J Alternat Complement Med. 2003;9:161–8.

    Article  Google Scholar 

  42. Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr. 2010;103:1545–57.

    Article  PubMed  Google Scholar 

  43. Al-Maweri SA. Efficacy of curcumin for management of oral submucous fibrosis: a systematic review of randomized clinical trials. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(4):300–8.

    Article  PubMed  Google Scholar 

  44. Kopuri RKC, Chakravarthy C, Sunder S, et al. A comparative study of the clinical efficacy of lycopene and curcumin in the treatment of oral submucous fibrosis using ultrasonography. J Int Oral Health. 2016;8:687.

    Google Scholar 

  45. Lanjekar AB, Bhowate RR, Bakhle S, Narayane A, Pawar V, Gandagule R. Comparison of efficacy of topical curcumin gel with triamcinolone-hyaluronidase gel individually and in combination in the treatment of oral submucous fibrosis. J Contemp Dent Pract. 2020;21(1):83–90.

    Article  PubMed  Google Scholar 

  46. Joshi J, Ghaisas SD, Vaidya A, et al. Early human safety of tumeric oil (Curcuma longa oil) administered orally in healthy volunteers. JAPI. 2003;51:1055–60.

    PubMed  Google Scholar 

  47. Hastak K, Lubri N, Jakhi SD, et al. Therapeutic responses to turmeric oil and turmeric oleoresin in oral submucos fibrosis. Amala Res Bullet. 1998;18:23–8.

    Google Scholar 

  48. Rai B, Kaur J, Jacobs R, Singh J. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci. 2010;52:251–6.

    Article  PubMed  Google Scholar 

  49. Yadav M, Aravinda K, Saxena VS, et al. Comparison of curcumin with intralesional steroid injections in oral submucous fibrosis—a randomized, open-label interventional study. J Oral Biol Craniofac Res. 2014;4:169–73.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Das DA, Balan A, Sreelatha KT. Comparative study of the efficacy of curcumin and turmeric oil as chemopreventive agents in oral submucous fibrosis: a clinical and histopathological evaluation. J Indian Acad Oral Med Radiol. 2010;22:88–92.

    Article  Google Scholar 

  51. Pipalia PR, Annigeri RG, Mehta R. Clinicobiochemical evaluation of turmeric with black pepper and nigella sativa in management of oral submucous fibrosis-a double-blind, randomized preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(6):705–12.

    Article  PubMed  Google Scholar 

  52. Piyush P, Mahajan A, Singh K, Ghosh S, Gupta S. Comparison of therapeutic response of lycopene and curcumin in oral submucous fibrosis: a randomized controlled trial. Oral Dis. 2019;25(1):73–9.

    Article  PubMed  Google Scholar 

  53. Hazarey VK, Sakrikar AR, Ganvir SM. Efficacy of curcumin in the treatment for oral submucous fibrosis—a randomized clinical trial. J Oral Maxillofac Pathol. 2015;19(2):145–52.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Nerkar Rajbhoj A, Kulkarni TM, Shete A, Shete M, Gore R, Sapkal R. A comparative study to evaluate efficacy of curcumin and aloe vera gel along with oral physiotherapy in the management of oral submucous fibrosis: a randomized clinical trial. Asian Pac J Cancer Prev. 2021;22(S1):107–12. https://doi.org/10.31557/APJCP.2021.22.S1.107.

    Article  PubMed  Google Scholar 

  55. Srivastava A, Agarwal R, Chaturvedi TP, Chandra A, Singh OP. Clinical evaluation of the role of tulsi and turmeric in the management of oral submucous fibrosis: a pilot, prospective observational study. J Ayurveda Integr Med. 2015;6(1):45–9.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Madhulatha G, Vijayalaxmi N, Harshavardhan T. Tulasi a magical herb and a boon for management of oral submucous fibrosis: a clinical study. Int J Res Med Sci. 2017;5(11):4719–23.

    Article  Google Scholar 

  57. Dwivedi N, Agarwal A. Aloe vera: magic or myth. SRM J Res Dent Sci. 2013;4:119.

    Article  Google Scholar 

  58. Miranda MS, Cintra RG, Barros SB, Mancini FJ. Antioxidant activity of the microalga Spirulina maxima. Braz J Med Biol Res. 1998;31:1075–9.

    Article  PubMed  Google Scholar 

  59. Anuradha A, Patil B, Asha VR. Evaluation of efficacy of aloe vera in the treatment of oral submucous fibrosis—a clinical study. J Oral Pathol Med. 2017;46(1):50–5.

    Article  PubMed  Google Scholar 

  60. Singh N, Hebbale M, Mhapuskar A, Ul Nisa S, Thopte S, Singh S. Effectiveness of aloe vera and antioxidant along with physiotherapy in the management of oral submucous fibrosis. J Contemp Dent Pract. 2016;17(1):78–84.

    Article  PubMed  Google Scholar 

  61. Sudarshan R, Annigeri RG, Sree VG. Aloe vera in the treatment for oral submucous fibrosis - a preliminary study. J Oral Pathol Med. 2012;41(10):755–61.

    Article  PubMed  Google Scholar 

  62. Alam S, Ali I, Giri KY, et al. Efficacy of aloe vera gel as an adjuvant treatment of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:717–24.

    Article  PubMed  Google Scholar 

  63. Patil S, Sghaireen MG, Maheshwari S, Kunsi SR, Sahu R. Comparative study of the efficacy of lycopene and aloe vera in the treatment of oral submucous fibrosis. Int J Health Allied Sci. 2015;4:13–7.

    Article  Google Scholar 

  64. Patil S, Al-Zarea BK, Maheshwari S, Sahu R. Comparative evaluation of natural antioxidants spirulina and aloe vera for the treatment of oral submucous fibrosis. J Oral Biol Craniofac Res. 2015;5(1):11–5.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Mulk BS, Deshpande P, Velpula N, Chappidi V, Chintamaneni RL, Goyal S. Spirulina and pentoxyfilline: a novel approach for treatment of oral submucous fibrosis. J Clin Diagn Res. 2013;7:3048–50.

    Google Scholar 

  66. Shetty P, Shenai P, Chatra L, Rao PK. Efficacy of spirulina as an antioxidant adjuvant to corticosteroid injection in management of oral submucous fibrosis. Indian J Dent Res. 2013;24:347–50.

    Article  PubMed  Google Scholar 

  67. Kanjani V, Annigeri RG, Revanappa MM, Rani A. Efficacy of spirulina along with different physiotherapeutic modalities in the management of oral submucous fibrosis. Ann Maxillofac Surg. 2019;9(1):23–7.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Kulkarni R, Kalaskar A, Kalaskar R, Gupta N. Efficacy of spirulina in management of oral submucous fibrosis—a systematic review. J Oral Med Oral Surg. 2022;28:8.

    Article  Google Scholar 

  69. More CB, Gavli N, Chen Y, Rao NR. A novel clinical protocol for therapeutic intervention in oral submucous fibrosis: an evidence-based approach. J Oral Maxillofac Pathol. 2018;22(3):382–91.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Fedorowicz Z, Chan Shih-Yen E, Dorri M, Nasser M, Newton T, Shi L. Interventions for the management of oral submucous fibrosis. Cochrane Database Syst Rev 2008;8(4):CD007156.

    Google Scholar 

  71. Li X, Tang J. Hua Xi, Kou Qiang, Xue Yi, Zhi Za. Clinical treatment observation of tea pigment for oral submucous fibrosis. West China J Stomatol. 1998;16(1):50–2.

    Google Scholar 

  72. Zhao Y, Guo Y, Gu X. Salvianolic acid B, a potential chemopreventive agent, for head and neck squamous cell cancer. J Oncol. 2011;2011:534548.

    Article  PubMed  Google Scholar 

  73. Hsieh YP, Wu KJ, Chen HM, Deng YT. Arecoline activates latent transforming growth factor β1 via mitochondrial reactive oxygen species in buccal fibroblasts: suppression by epigallocatechin-3-gallate. J Formos Med. 2018;117:527–34.

    Article  Google Scholar 

  74. Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res. 2006;17:190–8.

    Article  PubMed  Google Scholar 

  75. Mehrotra R, Singh HP, Gupta SC, Singh M, Jain S. Pentoxifylline therapy in the management of oral submucous fibrosis. Asian Pac J Cancer Prev. 2011;12:971–4.

    PubMed  Google Scholar 

  76. Sharma JK, Gupta AK, Mukhija RD, Nigam P. Clinical experience with the use of peripheral vasodilator in oral disorders. Int J Oral Maxillofac Surg. 1987;16:695–9.

    Article  PubMed  Google Scholar 

  77. Lai DR, Chen HR, Lin LM, Huang YL, Tsai CC. Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150 cases. J Oral Pathol Med. 1995;24:402–6.

    Article  PubMed  Google Scholar 

  78. Tan J, Li YC, Chen A, et al. Clinical research of Danxuan Koukang on treatment of oral submucous fibrosis. J Tradit Chin Med. 2006;26:41–3.

    Google Scholar 

  79. Singh U. Efficacy and safety of intralesional Xantinol nicotinate in the treatment of various stages of oral submucous fibrosis. J Clin Diagn Res. 2016;10(10):ZC34–ZC37.

    PubMed  PubMed Central  Google Scholar 

  80. Liu SF, Shen TH, Tang ZG, Su HP, Luo CF. On treatment of oral submucous fibrosis with glucosidorum tripterygii totorum. Beijing J Stomatol. 1999;7:167–9.

    Google Scholar 

  81. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol. 1994;30(4):603–21.

    Article  PubMed  Google Scholar 

  82. Zhou Q, Zheng F, Hou F. Inhibition of tubulointerstitial fibrosis by PTX is associated with improvement of vascular endothelial growth factor expression. Acta Pharmacol Sin. 2009;30(1):98–106.

    Article  PubMed  Google Scholar 

  83. Prabhu N, Rao SS, Kotrashetti SM, et al. PTX in patients with oral submucous fibrosis a randomized clinical trial. J Maxillofac Oral Surg. 2015;14(1):81–9.

    Google Scholar 

  84. Zwiri AMA, Patil S, Yadav N. Comparative evaluation of newer drugs pentoxifylline and spirulina in the management of OSMF. Int J Pharmacol Toxicol. 2015;5:141–5.

    Google Scholar 

  85. Patil S, Maheshwari S. Efficacy of pentoxifylline in the management of oral submucous fibrosis. J Orofac Sci. 2014;6:94–8.

    Article  Google Scholar 

  86. Sadaksharam J, Mahalingam S. Evaluation of oral PTX in the management of oral submucous fibrosis - an ultrasonographic study. Contemp Clin Dent. 2017;8(2):200–4.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Bhambal AM, Bhambal A, Shukla US, et al. Effectiveness of Pentoxifylline in the treatment of oral submucous fibrosis patients: a case-control study. Appl Cancer Res. 2019;39:15.

    Article  Google Scholar 

  88. Gopinath D, Hui LM, Veettil SK, Nair AB, Maharajan MK. Comparative efficacy of interventions for the management of oral submucous fibrosis: a systematic review and network meta-analysis. J Pers Med. 2022;12:1272.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Bishnoi S, Sharma M, Bishnoid S, Sharma Y. Drug pentoxifylline in management of oral submucous fibrosis. Int J Res Rev. 2020;7(4):311–4.

    Google Scholar 

  90. Leelakshi NB, Gaurav. Efficacy of garlic in conjunction with pentoxifylline in the management of oral submucous fibrosis—a cross-sectional pilot study. Acta Scientific Dental Sci. 2020;7(4):154–60.

    Google Scholar 

  91. Bhadage CJ, Umarji HR, Shah K, Valimaa H. Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis. Clin Oral Investig. 2013;17:1375–82.

    Article  PubMed  Google Scholar 

  92. Koneru A, Hunasgi S, Hallikeri K, Surekha R, Nellithady G, Vanishree M, et al. A systematic review of various treatment modalities for oral submucous fibrosis. J Adv Clin Res Insights. 2014;1:64–72.

    Article  Google Scholar 

  93. Johar N, Chaurasia S, Phulambrikar T. Management of oral submucous fibrosis: A Review. Int J Oral Health Dent. 2017;3(3):154–7.

    Google Scholar 

  94. Katharia SK, Singh SP, Kulshreshtha VK. The effects of placenta extract in management of oral submucous fibrosis. Indian J Pharmacol. 1992;24:181–3.

    Google Scholar 

  95. Kisave P, Shekhar V, Babu PS, Hussaini SW, Bhanot R, Kumar A, et al. The study of placentrex and hydrocortisone as an adjunct treatment in oral submucous fibrosis. J Family Med Prim Care. 2020;9:2469–74.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Rananjaneyulu P, Rao P. Submucous fibrosis new treatment. J Indian Dent Assoc. 1980;52:379–80.

    Google Scholar 

  97. Naik SM, Appaji MK, Ravishankara S, Goutham MK, Devi NP, Mushannavar AS, Naik SS. Comparative Study of intralesional triamcinolone acetonide and hyaluronidase vs placental extract in 60 cases of oral submucous fibrosis. Int J Head Neck Surg. 2012;3(2):59–65.

    Article  Google Scholar 

  98. Raj AG, Jayaprasad A, Manasa AM, Darshan DD, Ambili A. A longitudinal study of the effect of placental extract in the treatment of moderate and moderately advanced oral submucous fibrosis. RGUHS J Dent Sci. 2013;5(1):13–6.

    Google Scholar 

  99. Dinesh S, Sudhir P, Sara S, Nazima B, Sandeep KV, Aleem AK. Injection placentrex in the management of oral submucous fibrosis. Int J Modern Sci Eng Technol. 2015;2(1):23–30.

    Google Scholar 

  100. Priyankar S, Anil P, Ashish S, Tarun A, Sunil S, Sanjay RB, Mridula T. Efficacy of intralesional placental extract, dexamethasone, and hyaluronidase in treatment of oral submucous fibrosis: a comparative study. JK Pract. 2016;21(1–2):29–34.

    Google Scholar 

  101. Shah PH, Venkatesh R, More CB, Vassandacoumara V. Comparison of therapeutic efficacy of placental extract with dexamethasone and hyaluronic acid with dexamethasone for oral submucous fibrosis—a retrospective analysis. J Clin Diagn Res 2016;10(10):ZC63–ZC66.

    Google Scholar 

  102. Shinde CV, Saawarn N, Kohli S, Khare P, Singh A, Sagar KM. Comparative efficacy of intralesional placental extract and intralesional triamcinolone acetonide in the management of OSMF. J Indian Acad Oral Med Radiol. 2019;31:328–32.

    Article  Google Scholar 

  103. Kale MV, Gaikwad NS. Oral submucous fibrosis: a study of qualitative and analytical treatment using intralesional injections: placental extract versus combination of steroid with hyaluronidase. Int J Otorhinolaryngol Head Neck Surg. 2020;6(7):1321–5.

    Article  Google Scholar 

  104. Borle RM, Borle SR. Management of oral submucous fibrosis: a conservative approach. J Oral Maxillofac Surg. 1991;49:788–91.

    Article  PubMed  Google Scholar 

  105. Reddi R. Oral Submucous Fibrosis - A recent trend in its treatment. JIAOMR. 1993;4:7–8.

    Google Scholar 

  106. Nallapu V, Balasankulu B, Vuppalapati HB, Sambhana S, Mala D, Koppula SK. Efficacy of vitamin E in oral submucous fibrosis: a clinical and histopathologic study. J Indian Acad Oral Med Radiol. 2015;27:387–92.

    Article  Google Scholar 

  107. Singh N, Singh J, Singh U. Oral sub mucous fibrosis. A new approach to treatment with combined therapy. J Indian Dent Assoc. 1996;67:168–70.

    Google Scholar 

  108. Nayak A, Anitha B, Bhattacharya A, Podder S. Efficacy of lycopene in combination with vitamin E in management of oral submucous fibrosis—a clinical prospective study. J Adv Med Dent Sci Res. 2015;3(3):21–5.

    Google Scholar 

  109. Thakur N, Keluskar V, Bagewadi A, Shetti A. Effectiveness of micronutrients and physiotherapy in the management of oral submucous fibrosis. Int Nat Contemp Dentist. 2011;2(1):101–5.

    Google Scholar 

  110. Raizada MK, Sable DM. Clinical assessment of efficacy of Omega 3 in oral submucous fibrosis patients—a randomized controlled trial. Asian Pac J Cancer Prev. 2022;23(4):1185–92.

    Article  PubMed  Google Scholar 

  111. Nagaraj T, Santosh HN. Estimation of serum hepcidin in oral submucous fibrosis before and after supplementation with oral iron: a randomized control clinical trial. J Oral Maxillofac Pathol. 2018;22(3):303–6.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Maher R, Aga P, Johnson NW, Sankaranarayanan R, Warnakulasuriya S. Evaluation of multiple micronutrient supplementation in the management of oral submucous fibrosis in Karachi. Pakistan Nutr Cancer. 1997;27(1):41–7.

    Article  PubMed  Google Scholar 

  113. Dhariwal R, Mukherjee S, Mohanty S, Chakraborty A, Ray J, Chaudhuri K. Zinc and vitamin A can minimise the severity of oral submucous fibrosis. BMJ Case Rep. 2010:bcr1020092348.

    Google Scholar 

  114. Anil K, Sharma SC, Sharma P, Chandra O, Singhal KC, Nagar A. Beneficial role of zinc in the treatement of oral submucous fibrosis. Indian J Pharmac. 1991;23:236–41.

    Google Scholar 

  115. Singh BP, Mittal N, Sharma V, Palani. Evaluation of role of Oxitard capsules in the treatment of oral submucous fibrosis. Antiseptic. 2009;106:103–7.

    Google Scholar 

  116. Patil S, Santosh BS, Maheshwari S, Deoghare A, Chhugani S, Rajesh PR. Efficacy of oxitard capsules in the treatment of oral submucous fibrosis. J Canc Res Therapeut. 2015;11(2):291–4.

    Article  Google Scholar 

  117. Patil S, Halgatti V, Maheshwari S, Santosh BS. Comparative study of the efficacy of herbal antioxdants oxitard and aloe vera in the treatment of oral submucous fibrosis. J Clin Exp Dent. 2014;6(3):e265–70.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Sasi M, Kumar S, Kumar M, Thapa S, Prajapati U, Tak Y, et al. Garlic (Allium sativum L.) Bioactives and its role in alleviating oral pathologies. Antioxidants (Basel). 2021;10(11):1847.

    Google Scholar 

  119. Jiang X, Zhang Y, Li F, Zhu Y, Chen Y, Yang S, Sun G. Allicin as a possible adjunctive therapeutic drug for stage II oral submucous fibrosis: a preliminary clinical trial in a Chinese cohort. Int J Oral Maxillofac Surg. 2015;44:1540–6.

    Article  PubMed  Google Scholar 

  120. Jiang XW, Zhang Y, Song GD, Li FF, Peng HY, Yang SK, Sun GL. Clinical evaluation of allicin oral adhesive tablets in the treatment of recurrent aphthous ulceration. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:500–4.

    Article  PubMed  Google Scholar 

  121. Jain N, Annigeri RG, Pipalia PR. Efficacy of garlic in conjunction with pentoxifylline in the management of oral submucous fibrosis—a preliminary study. Int J Pharm Sci Res. 2016;7:5017.

    Google Scholar 

  122. Cabras M, Carrozzo M, Gambino A, Broccoletti R, Sciascia S, Baldovino S, Arduino PG. Value of colchicine as treatment for recurrent oral ulcers: a systematic review. J Oral Pathol Med. 2020;49(8):731–40.

    Article  PubMed  Google Scholar 

  123. Segovia A, Niembro RF, Ibanez KG, Alcocer G, Tamayo P. Long term evaluation of colchicine in the treatment of scleroderma. J Rheumatol. 1979;6:705–12.

    Google Scholar 

  124. Diegelmann RF, Peterkofsky B. Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular descriptive drugs. Proc Natl Acad Sci U S A. 1972;69:892–6.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Daga D, Singh RK, Pal US, Gurung T, Gangwar S. Efficacy of oral colchicine with intralesional hyaluronidase or triamcinolone acetonide in the Grade II oral submucous fibrosis. Natl J Maxillofac Surg. 2017;8(1):50–4.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Stewart S, Yang KCK, Atkins K, et al. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22:28.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Haque MF, Meghji S, Nazir R, Harris M. Interferon-gamma (IFN-gamma) may reverse oral submucous fibrosis. J Oral Pathol Med. 2001;30:12–21.

    Article  PubMed  Google Scholar 

  128. Sheshaprasad R, Pai A. Oral sub mucous fibrosis: exploring therapeutic strategies using -anti TGF β drugs. Asian Pac J Cancer Care. 2018;3(2):21–7.

    Article  Google Scholar 

  129. Moinzadeh P, Hunzelmann N, Krieg T. Pharmacology and rationale for imatinib in the treatment of scleroderma. J Exp Pharmacol. 2013;5:15–22.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60(1):219–24.

    Article  PubMed  Google Scholar 

  131. Gan Y, Herzog EL, Gomer RH. Pirfenidone treatment of idiopathic pulmonary fibrosis. Therap Clin Risk Manage. 2011;7:39–47.

    Google Scholar 

  132. Garcia L, Hernandez I, Sandoval A, Salazar A, Garcia J, Vera J, et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol. 2002;37(6):797–805.

    Article  PubMed  Google Scholar 

  133. Yu CC, Tsai CH, Hsu HI, Chang YC. Elevation of S100A4 expression in buccal mucosal fibroblasts by arecoline: involvement in the pathogenesis of oral sub mucous fibrosis. PLoS One. 2013;8(1):e55122.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002;446(1–3):177–85.

    Article  PubMed  Google Scholar 

  135. Kaur J, Jacobs R. Proinflammatory cytokine levels in oral lichen planus, oral leukoplakia, and oral sub mucous fibrosis. J Korean Assoc Oral Maxillofac Surg. 2015;41(4):171–5.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Bishen KA, Radhakrishnan R, Satyamoorthy K. The role of basic fibroblast growth factor in oral submucous fibrosis pathogenesis. J Oral Pathol Med. 2008;37(7):402–11.

    Article  PubMed  Google Scholar 

  137. Tsai CH, Lee SS, Chang YC. Hypoxic regulation of plasminogen activator inhibitor-1 expression in human buccal mucosa fibroblasts stimulated with arecoline. J Oral Pathol Med. 2015;44(9):669–73.

    Article  PubMed  Google Scholar 

  138. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–82.

    Article  PubMed  Google Scholar 

  139. Seema Nayak MMG, Makker A, Bhatia V, Chandra S, Sandeep Kumar SP, Agarwal. Fibroblast Growth Factor (FGF-2) and its receptors FGFR-2 and FGFR-3 may be putative biomarkers of malignant transformation of potentially malignant oral lesions into oral squamous cell carcinoma. PLoS One. 2015;

    Google Scholar 

  140. Haque MF, Meghji S, Khitab U, Harris M. Oral submucous fibrosis patients have altered levels of cytokine production. J Oral Pathol Med. 2000;29(3):123–8.

    Article  PubMed  Google Scholar 

  141. Hajari Case A, Johnson P. Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis. BMJ Open. Respir Res. 2017;4(1)

    Google Scholar 

  142. Joshi M, Patravale V. Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of valdecoxib. Drug Dev Ind Pharmacy. 2006;32:911–8.

    Article  Google Scholar 

  143. Averineni RK, Sunderajan SG, Mutalik S, et al. Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study. Pharm Dev Technol. 2009;14:199–207.

    Article  PubMed  Google Scholar 

  144. Gopinath D, Hui LM, Veettil SK, Balakrishnan Nair A, Maharajan MK. Comparative efficacy of interventions for the management of oral submucous fibrosis: a systematic review and network meta-analysis. J Pers Med. 2022;12(8):1272.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oral and Maxillofacial Pathology, Ragas Dental College and Hospital, The Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu, India

    Kavitha Loganathan & Kannan Ranganathan

Authors
  1. Kavitha Loganathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kannan Ranganathan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kavitha Loganathan .

Editor information

Editors and Affiliations

  1. Faculty of Dentistry Oral and Craniofacial Sciences, King's College London, London, UK

    Saman Warnakulasuriya

  2. Oral and Maxillofacial Pathology, Ragas Dental College and Hospital, The TN Dr MGR Medical University, Chennai, Tamil Nadu, India

    Kannan Ranganathan

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Loganathan, K., Ranganathan, K. (2023). Medical Management of Oral Submucous Fibrosis. In: Warnakulasuriya, S., Ranganathan, K. (eds) Oral Submucous Fibrosis. Textbooks in Contemporary Dentistry. Springer, Cham. https://doi.org/10.1007/978-3-031-12855-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-12855-4_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-12854-7

  • Online ISBN: 978-3-031-12855-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation